FMP

FMP

Enter

GUD.TO - Knight Therapeutics ...

photo-url-https://images.financialmodelingprep.com/symbol/GUD.TO.png

Knight Therapeutics Inc.

GUD.TO

TSX

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

6 CAD

-0.1 (-1.67%)

Operating Data

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

199.52M

243.48M

293.56M

328.2M

371.3M

433.99M

507.27M

592.92M

693.02M

810.03M

Revenue %

-

22.03

20.57

11.8

13.13

16.88

16.88

16.88

16.88

Ebitda

67.56M

42.59M

25.26M

40.9M

64.38M

77.91M

91.06M

106.44M

124.41M

145.42M

Ebitda %

33.86

17.49

8.6

12.46

17.34

17.95

17.95

17.95

17.95

Ebit

35.48M

-5.32M

-37.36M

-9.5M

11.28M

2.62M

3.06M

3.57M

4.18M

4.88M

Ebit %

17.78

-2.19

-12.73

-2.89

3.04

0.6

0.6

0.6

0.6

Depreciation

32.08M

47.91M

62.62M

50.4M

53.11M

75.29M

88.01M

102.87M

120.23M

140.53M

Depreciation %

16.08

19.68

21.33

15.36

14.3

17.35

17.35

17.35

17.35

Balance Sheet

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Total Cash

411.34M

162.99M

191.22M

154.42M

172.84M

282.69M

330.42M

386.2M

451.41M

527.62M

Total Cash %

206.17

66.94

65.14

47.05

46.55

65.14

65.14

65.14

65.14

Receivables

82.04M

67.41M

94.89M

98.23M

113.53M

140.3M

163.99M

191.68M

224.04M

261.87M

Receivables %

41.12

27.69

32.32

29.93

30.58

32.33

32.33

32.33

32.33

Inventories

56.51M

72.4M

92.49M

91.83M

102.7M

126.03M

147.31M

172.18M

201.25M

235.23M

Inventories %

28.32

29.73

31.51

27.98

27.66

29.04

29.04

29.04

29.04

Payable

44.51M

65.31M

106.06M

85.37M

78.34M

114.9M

134.3M

156.97M

183.47M

214.45M

Payable %

22.31

26.82

36.13

26.01

21.1

26.47

26.47

26.47

26.47

Cap Ex

-20.67M

-224.18M

-25.82M

-9.96M

-31.47M

-106.54M

-124.52M

-145.55M

-170.12M

-198.84M

Cap Ex %

-10.36

-92.08

-8.79

-3.03

-8.48

-24.55

-24.55

-24.55

-24.55

Weighted Average Cost Of Capital

Price

6

Beta

Diluted Shares Outstanding

101.13M

Costof Debt

18.65

Tax Rate

After Tax Cost Of Debt

18.65

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

49.46M

Total Equity

606.8M

Total Capital

656.26M

Debt Weighting

7.54

Equity Weighting

92.46

Wacc

6.43

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

199.52M

243.48M

293.56M

328.2M

371.3M

433.99M

507.27M

592.92M

693.02M

810.03M

Ebitda

67.56M

42.59M

25.26M

40.9M

64.38M

77.91M

91.06M

106.44M

124.41M

145.42M

Ebit

35.48M

-5.32M

-37.36M

-9.5M

11.28M

2.62M

3.06M

3.57M

4.18M

4.88M

Tax Rate

-111.11

-111.11

-111.11

-111.11

-111.11

-111.11

-111.11

-111.11

-111.11

-111.11

Ebiat

35.12M

-12.47M

-25.4M

-7.27M

23.8M

2.32M

2.71M

3.17M

3.71M

4.33M

Depreciation

32.08M

47.91M

62.62M

50.4M

53.11M

75.29M

88.01M

102.87M

120.23M

140.53M

Receivables

82.04M

67.41M

94.89M

98.23M

113.53M

140.3M

163.99M

191.68M

224.04M

261.87M

Inventories

56.51M

72.4M

92.49M

91.83M

102.7M

126.03M

147.31M

172.18M

201.25M

235.23M

Payable

44.51M

65.31M

106.06M

85.37M

78.34M

114.9M

134.3M

156.97M

183.47M

214.45M

Cap Ex

-20.67M

-224.18M

-25.82M

-9.96M

-31.47M

-106.54M

-124.52M

-145.55M

-170.12M

-198.84M

Ufcf

-47.51M

-169.2M

4.58M

9.79M

12.25M

-42.47M

-59.37M

-69.4M

-81.11M

-94.81M

Wacc

6.43

6.43

6.43

6.43

6.43

Pv Ufcf

-39.9M

-52.41M

-57.56M

-63.22M

-69.43M

Sum Pv Ufcf

-282.49M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

6.43

Free Cash Flow T1

-96.7M

Terminal Value

-2.18B

Present Terminal Value

-1.6B

Intrinsic Value

Enterprise Value

-1.88B

Net Debt

-30.65M

Equity Value

-1.85B

Diluted Shares Outstanding

101.13M

Equity Value Per Share

-18.28

Projected DCF

-18.28 1.328%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep